Zealand Pharma has reported royalty revenue from Sanofi’s sales of Lyxumia (lixisenatide) outside the United States of €0.7 million for Q4 2016 and annual royalty revenue of €3.3 million in 2016.
Lixisenatide is type 2 diabetes drug invented by Zealand. Zealand licensed the global development and commercialization rights to lixisenatide to Sanofi. Lixisenatide is marketed under the brand name Lyxumia in over 45 countries and was launched in the United States under the brand name Adlyxin in January 2017.
Sanofi has also developed a combination of lixisenatide and insulin glargine 100 units/mL (Lantus), which was approved by: the US Food and Drug Administration in November 2016 and is being marketed under the brand name Soliqua 100/33 in the United States.
In January 2017 Sanofi won European Commission marketing authorization for Suliqua which triggered a $10 million milestone payment to Zealand Pharma.
Sanofi has announced that it expects to launch marketing of Suliqua in certain EU countries in the second quarter of 2017.